Immunological non-inferiority of a new fully liquid presentation of the MenACWY-CRM vaccine to the licensed vaccine: results from a randomized, controlled, observer-blind study in adolescents and young adults.

Saved in:

Bibliographic Details
Title:	Immunological non-inferiority of a new fully liquid presentation of the MenACWY-CRM vaccine to the licensed vaccine: results from a randomized, controlled, observer-blind study in adolescents and young adults.
Authors:	Díez-Domingo J; Vaccine Research Area, FISABIO-Public Health, Valencia, Spain., Tinoco JC; Infectious Disease, Hospital General de Durango, Durango, Mexico., Poder A; Kliiniliste Uuringute Keskus, Tartu, Estonia., Dinleyici EC; Pediatrics, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey., Nell H; Tiervlei Trial Centre, Karl Bremer Hospital, Bellville, South Africa., Salamanca de la Cueva I; Instituto Hispalense de Pediatria, Seville, Spain., Ince T; Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey., Moreira ED Jr; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Brazilian Ministry of Health, Salvador, Brazil., Ahmed K; Setshaba Research Centre, Tshwane, and Faculty of Health Sciences, Department of Medical Microbiology, University of Pretoria, Pretoria, South Africa., Luz K; Centro de Pesquisas Clinicas de Natal, Rio Grande do Norta, Brazil., Kovshirina Y; Infectious Diseases and Epidemiology, Siberian State Medical University, Tomsk, Russian Federation., Medina Pech CE; Medical Care and Research SA de CV, Mérida, Mexico., Akhund T; Clinical Research and Development Centre, GSK, Siena, Italy., Romolini V; Biostatistics, GSK, Siena, Italy., Costantini M; Biostatistics, GSK, Siena, Italy., Mzolo T; Biostatistics, GSK, Amsterdam, The Netherlands., Kunnel B; Data Strategy & Management, Global Clinical Operations Development - R&D, GSK, Amsterdam, The Netherlands., Lechevin I; Clinical Laboratory Sciences, GSK, Rixensart, Belgium., Aggravi M; Technical Development, GSK, Siena, Italy., Tiberi P; Safety Evaluation and Risk Management, GSK, Siena, Italy., Narendran K; Global Clinical Operations, GSK, Bangalore, India., García-Martínez JA; Medical Department, GSK, Madrid, Spain., Basile V; Global Clinical Delivery, Global Clinical Operations Development, GSK, Siena, Italy., Fragapane E; Clinical Research and Development Centre, GSK, Siena, Italy., Lattanzi M; Clinical Research and Development Centre, GSK, Siena, Italy., Pellegrini M; Clinical Research and Development Centre, GSK, Siena, Italy.
Source:	Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2022 Dec 31; Vol. 18 (1), pp. 1981085. Date of Electronic Publication: 2021 Oct 06.
Publication Type:	Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Equivalence Trial
Journal Info:	Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	2164-554X
DOI:	10.1080/21645515.2021.1981085